Summit Therapeutics Inc. Increase (Decrease) in Income Taxes Receivable
Summit Therapeutics Inc. (SMMT) reported Increase (Decrease) in Income Taxes Receivable of $4.38 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2021-03-31
- Summit Therapeutics Inc. increase (decrease) in income taxes receivable for the quarter ending 2020-12-31 was $884.00K.
- Summit Therapeutics Inc. increase (decrease) in income taxes receivable for the quarter ending 2020-09-30 was -$966.00K, a 150.68% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in income taxes receivable for the quarter ending 2019-09-30 was $1.91M.
- Summit Therapeutics Inc. increase (decrease) in income taxes receivable for fiscal 2020 was $4.38M.
- Summit Therapeutics Inc. increase (decrease) in income taxes receivable for fiscal 2019 was $2.22M.
| Period end | Increase (Decrease) in Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Receivable 11 month | Increase (Decrease) in Income Taxes Receivable 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | $884.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$82.00K derived: sum of 2 quarters · filed 2021-03-31 | $4.38M 10-K · filed 2021-03-31 | ||
| 2020-09-30 | -$966.00K derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | $3.50M 10-Q · filed 2020-11-16 | |||
| 2020-06-30 | $4.46M 8-K · filed 2020-09-29 | ||||
| 2019-12-31 | -$3.15M 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | $1.91M derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | -$1.81M 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | -$3.71M 8-K · filed 2020-09-29 | ||||
| 2019-01-31 | $2.22M 10-K · filed 2021-03-31 | ||||
| 2018-01-31 | $683.00K 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |